Bangkok Genomics Innovation PCL (BKGI.BK) Stock Price
Bangkok Genomics Innovation PCL Price
Revenue has compounded at 27.1% per year over the past 7 years to 379.51 M THB. Earnings per share have grown at 19.6% per year over the last 6 years. Bangkok Genomics Innovation PCL's net margin stands at 11.9%, down from 27.9% several years earlier. Bangkok Genomics Innovation PCL currently offers a dividend yield of about 2.10%. The payout ratio is around 66% of earnings. Analysts set a median price target of 1.73 THB, implying 27.1% below the current price. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus.
Bangkok Genomics Innovation PCL stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Bangkok Genomics Innovation PCL business model & stock analysis
Frequently asked questions about Bangkok Genomics Innovation PCL
Analysts currently set an average price target of 1.73 THB for the Bangkok Genomics Innovation PCL stock (median: 1.73 THB), implying -27.1 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Bangkok Genomics Innovation PCL stock: 0 recommend buying, 3 holding and 6 selling. For 2026, analysts expect Bangkok Genomics Innovation PCL to generate revenue of 400.00 M THB and earnings per share of 0.10 THB.
Converted at the current exchange rate, the Bangkok Genomics Innovation PCL share trades at 0.06 EUR (2.38 THB).
The expected revenue of Bangkok Genomics Innovation PCL is 400.00 M THB. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Bangkok Genomics Innovation PCL is 60.00 M THB. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Bangkok Genomics Innovation PCL is currently 23.80. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bangkok Genomics Innovation PCL stock.
The price-to-sales ratio (P/S) of Bangkok Genomics Innovation PCL is currently 3.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bangkok Genomics Innovation PCL stock.
The Eulerpool Quality Score for Bangkok Genomics Innovation PCL is 2/10.
The ISIN of Bangkok Genomics Innovation PCL is THB972010003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Bangkok Genomics Innovation PCL is BKGI.BK. The ticker symbol is used to trade Bangkok Genomics Innovation PCL shares on the stock exchange.
Bangkok Genomics Innovation PCL stock
Bangkok Genomics Innovation PCL Peer Group
All fundamentals and in-depth analysis of Bangkok Genomics Innovation PCL
Our stock analysis for Bangkok Genomics Innovation PCL stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bangkok Genomics Innovation PCL. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.